Johnson & Johnson (JNJ) Shares Dip After Revenue Miss, Suspended COVID Vaccine Sales Guidance; Results Seen as 'Mixed'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Johnson & Johnson (JNJ) PT Raised to $205 at Credit Suisse
April 20, 2022 6:51 AM EDTCredit Suisse analyst Matt Miksic raised the price target on Johnson & Johnson (NYSE: JNJ) to $205.00 (from $200.00) while maintaining a Outperform rating.
... MoreJohnson & Johnson (JNJ) PT Raised to $196 at Raymond James
April 20, 2022 5:56 AM EDTRaymond James analyst Jayson Bedford raised the price target on Johnson & Johnson (NYSE: JNJ) to $196.00 (from $195.00) while maintaining a Outperform rating following results.
The analyst commented, "1Q results were mixed and the downward guidance revision, although not operational, still causes us to... More
Johnson & Johnson (JNJ) PT Raised to $210 at Citi
April 19, 2022 3:11 PM EDTCiti analyst Joanna Wuensch raised the price target on Johnson & Johnson (NYSE: JNJ) to $210.00 (from $203.00) while maintaining a Buy rating following earnings.
... More